191 related articles for article (PubMed ID: 8738315)
1. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.
Conus P; Bondolfi G; Eap CB; Macciardi F; Baumann P
Pharmacopsychiatry; 1996 May; 29(3):108-10. PubMed ID: 8738315
[TBL] [Abstract][Full Text] [Related]
2. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.
Baumann P; Broly F; Kosel M; Eap CB
Pharmacopsychiatry; 1998 Mar; 31(2):72. PubMed ID: 9562213
[No Abstract] [Full Text] [Related]
3. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
[TBL] [Abstract][Full Text] [Related]
4. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
[TBL] [Abstract][Full Text] [Related]
5. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype.
Haffen E; Vandel P; Broly F; Vandel S; Sechter D; Bizouard P; Bechtel PR
Pharmacopsychiatry; 1999 Nov; 32(6):232-4. PubMed ID: 10599932
[TBL] [Abstract][Full Text] [Related]
6. [Grapefruit juice as a contraindication? An approach in psychiatry].
Vandel P; Regina W; Reix I; Vandel S; Sechter D; Bizouard P
Encephale; 1999; 25(1):67-71. PubMed ID: 10205736
[TBL] [Abstract][Full Text] [Related]
7. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
[TBL] [Abstract][Full Text] [Related]
8. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy.
Miljković BR; Pokrajac M; Timotijević I; Varagić V
Int Clin Psychopharmacol; 1997 Jul; 12(4):207-12. PubMed ID: 9347381
[TBL] [Abstract][Full Text] [Related]
9. When fluvoxamine treats only depression and clomipramine treats only obsessive-compulsive disorder--combine them?
Schaller JL; Behar D; Chamberlain T
J Neuropsychiatry Clin Neurosci; 1998; 10(1):111-3. PubMed ID: 9547477
[No Abstract] [Full Text] [Related]
10. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
Brown JT; Schneiderhan M; Eum S; Bishop JR
Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
[TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.
Vandel S; Bertschy G; Baumann P; Bouquet S; Bonin B; Francois T; Sechter D; Bizouard P
Pharmacol Res; 1995 Jun; 31(6):347-53. PubMed ID: 8685072
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
14. Lack of desipramine toxicity with citalopram.
Ashton AK
J Clin Psychiatry; 2000 Feb; 61(2):144. PubMed ID: 10732663
[No Abstract] [Full Text] [Related]
15. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration.
Birkenhäger TK; van den Broek WW; Fekkes D; Mulder PG; Moleman P; Bruijn JA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1084-8. PubMed ID: 17467132
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M
J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
[TBL] [Abstract][Full Text] [Related]
18. [Cytochrome p450 IID6, its role in psychopharmacology].
Lamard L; Pérault MC; Bouquet S; Guibert S
Ann Med Psychol (Paris); 1995 Feb; 153(2):140-3. PubMed ID: 7741408
[TBL] [Abstract][Full Text] [Related]
19. Interaction of modafinil and clomipramine as comedication in a narcoleptic patient.
Grözinger M; Härtter S; Hiemke C; Griese EU; Röschke J
Clin Neuropharmacol; 1998; 21(2):127-9. PubMed ID: 9579300
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane CL; Gill HS
J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
